I-Mab Most Recent Clinical Data Update Conference Call -- English Session Transcript

Dec 14, 2021 / 01:00PM GMT
Tianyi Zhang - I-Mab - Executive Director of IR

Good day, ladies and gentlemen. Thank you for standing by. This is Tianyi Zhang, IR Head of I-Mab Biopharma. Thank you for joining the conference call today.

Yesterday, I-Mab presented clinical data of lemzoparlimab in combination with rituximab in NHL patients at ASH meeting. Today's conference, we will have the management team to give you more insights of the clinical data and the future development plan. Joining me today on the call from I-Mab's senior management team include Dr. Jingwu Zhang, Founder and Chairman of I-Mab; Dr. Joan Shen, CEO of I-Mab; I-Mab; and Mr. John Long, Chief Financial Officer of I-Mab.

Today's conference call will be divided into 2 parts. First, the management team will give an in-depth overview of the clinical data, and it will be followed by a Q&A session.

Now I'd like to turn the call to Dr. Jingwu Zhang, Founder and Chairman of I-Mab, to share with you more details about the clinical trial.

Jingwu Zhang Zang - I-Mab - Founder & Chairman

Thank you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot